Study Caract. | Arguedas (1991) | Aronovitz (1992) | Gehanno (1994) | Hedrik (2001) | Kafetzis (1994) | Kafetzis (1994) | Stutman (1992) |
Country | USA | USA and European countries | France | USA | USA, Dominican epublic, Greece | France, Netherlands | USA |
Number of participants | 122 | 334 | 191 | 303 | 463 | 361 | 530 |
Ages | 6 months - 17 years | 3 years - 11 years | 6 months and older | 6 months - 7 years | 4 months - 13 years | 4 months - 11 years | 6 months - 13 years |
Duration of treatment | 10 days | 10 days | 7 - 9 days | 10 days | 10 days | 10 days | 10 days |
Dose | C: 30 mg/kg/day A/C: 40 mg/kg/day | C: 30 mg/kg/day A/C: 40 mg/kg/day | C: 40 mg/kg/day A/C: 40 mg/kg/day | C: 30 mg/kg/day A/C: 45/6.4 mg/kg/day + C 45/mg/day | C: 30 mg/kg/day A/C: 40 mg/kg/day | C: 40 mg/kg/day A/C: 40 mg/kg/day | C: 30 mg/kg/day A/C: 40 mg/kg/day |
Clinical response | C: 58/60 (96.7%) A/C: 53/62 (91.3%) | C: 141/168 (84%) A/C: 129/166 (78%) | C: 83/99 (84%) A/C: 80/92 (87%) | 6 months - 2 years C: 59/70 (80%) A/C: 64/76 (86%) 2 years - 7 years C: 68/80 (93%) A/C: 66/77 (92%) | C: 186/223 (83%) A/C: 193/243 (79%) | C: 145/174 (83%) A/C: 147/176 (84%) | C: 141/168 (84%) A/C: 129/166 (78%) |
Bacterial response | C: 57/60 (95%) A/C: 57/62 (91.3%) | C: 142/168 (85%) A/C: 136/166 (81%) | C: 115/130 (88%) A/C: 118/132 (89%) | No presented data | C: 158/188 (84%) A/C: 171/214 (80%) | C: 109/131 (83%) A/C: 111/214 (80%) | C: 165/193 (85%) A/C: 149/182 (82%) |
Frequency of adverse effects | C: 20/60 (33%) A/C: 43/62 (69%) | <3 years C: 35/160 (22%) A/C: 56/163 (34%) >3 years C: 8/103 (8%) A/C: 18/104 (17%) | <3 years C: 21/114 (18%) A/C: 36/131 (27%) >3 years C: 14/69 (20%) A/C: 14/47 (30%) | C: 28/150 (19%) A/C: 49/153 (32%) | C: 32/223 (14%) A/C: 86/243 (35%) | C: 24/183 (13%) A/C: 36/178 (20%) | <3 years C: 37/160 (23%) A/C: 72/163 (44%) >3 years C: 5/103 (5%) A/C: 17/104 (16%) |